81 related articles for article (PubMed ID: 18989155)
1. Osteonecrosis in children treated for lymphoma or solid tumors.
Niinimäki RA; Harila-Saari AH; Jartti AE; Seuri RM; Riikonen PV; Pääkkö EL; Möttönen MI; Lanning M
J Pediatr Hematol Oncol; 2008 Nov; 30(11):798-802. PubMed ID: 18989155
[TBL] [Abstract][Full Text] [Related]
2. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Kamieńska E
Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
[TBL] [Abstract][Full Text] [Related]
3. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.
Niinimäki RA; Harila-Saari AH; Jartti AE; Seuri RM; Riikonen PV; Pääkkö EL; Möttönen MI; Lanning M
J Clin Oncol; 2007 Apr; 25(12):1498-504. PubMed ID: 17442991
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or non-Hodgkin-lymphoma treated with hyperbaric-oxygen-therapy (HBO): an approach to cure? -- BME/AON and hyperbaric oxygen therapy as a treatment modality.
Bernbeck B; Christaras A; Krauth K; Lentrodt S; Strelow H; Schaper J; Janssen G; Mödder U; Göbel U
Klin Padiatr; 2004; 216(6):370-8. PubMed ID: 15565553
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.
Aricò M; Boccalatte MF; Silvestri D; Barisone E; Messina C; Chiesa R; Santoro N; Tamaro P; Lippi A; Gallisai D; Basso G; De Rossi G;
Haematologica; 2003 Jul; 88(7):747-53. PubMed ID: 12857552
[TBL] [Abstract][Full Text] [Related]
6. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
11. [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].
Bence Z; Kovács G; Jakab Z; Csóka M; Müller J
Magy Onkol; 2008 Dec; 52(4):357-62. PubMed ID: 19068463
[TBL] [Abstract][Full Text] [Related]
12. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
14. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
17. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
Glanzmann C; Veraguth A; Lütolf UM
Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.
te Winkel ML; Pieters R; Hop WC; de Groot-Kruseman HA; Lequin MH; van der Sluis IM; Bökkerink JP; Leeuw JA; Bruin MC; Egeler RM; Veerman AJ; van den Heuvel-Eibrink MM
J Clin Oncol; 2011 Nov; 29(31):4143-50. PubMed ID: 21947829
[TBL] [Abstract][Full Text] [Related]
19. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors.
Meadows AT; Obringer AC; Marrero O; Oberlin O; Robison L; Fossati-Bellani F; Green D; Voûte PA; Morris-Jones P; Greenberg M
Med Pediatr Oncol; 1989; 17(6):477-84. PubMed ID: 2586362
[TBL] [Abstract][Full Text] [Related]
20. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis.
Hemminki K; Lenner P; Sundquist J; Bermejo JL
J Clin Oncol; 2008 Apr; 26(11):1850-7. PubMed ID: 18347006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
